Overview

Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma

Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the ability to combine a radioactive medication directly targeted against lymphoma cells with the immune effects of an allogeneic blood stem cell transplant.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Maisonneuve-Rosemont Hospital
Collaborator:
Bayer
Treatments:
Antibodies, Monoclonal
Cyclophosphamide
Fludarabine
Rituximab